0

Rigel Pharmaceuticals Inc (RIGL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Publisher Name :
Date: 18-May-2017
No. of pages: 50

Summary

Rigel Pharmaceuticals Inc (Rigel or ‘the company’) is a clinical-stage drug development company engaged in the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. The company operates in the US, where it is headquartered in South San Francisco, California. It employed 126 people as of December 31, 2015.

Rigel Pharmaceuticals Inc (RIGL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

– Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
– Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
– Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
– Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
– Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
– Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
– Business Description – A brief description of the company’s operations.
– Key Employees – A list of the key executives of the company.
– Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
– Key Competitors – A list of the key competitors of the company.
– Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
– The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
– The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
– Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
– Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
– Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of content
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Rigel Enters into R&D Agreement with Bristol-Myers Squibb for TGF Beta Receptor Kinase Inhibitors 11
Proteros Biostructures Extends Collaboration With Rigel Pharma 11
Licensing Agreements 12
Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 12
AstraZeneca Enters Into Licensing Agreement With Rigel Pharma For R256 13
Rigel Pharma Enters Into Licensing Agreement With BerGenBio For BGB324 14
Equity Offering 15
Rigel Pharma Raises USD46 Million in Public Offering of Shares 15
Rigel Pharma to Raise up to USD30 Million in Private Placement of Shares 17
Rigel Pharma Completes Public Offering Of Shares For US$145 Million 18
Rigel Pharma Completes An Underwritten Public Offering Of US$130.4 Million 19
Rigel Pharmaceuticals Inc - Key Competitors 21
Key Employees 22
Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
May 02, 2017: Rigel Announces First Quarter 2017 Financial Results and Provides Company Update 24
Mar 07, 2017: Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results 26
Nov 01, 2016: Rigel Announces Third Quarter 2016 Financial Results and Provides Company Update 28
Aug 02, 2016: Rigel Announces Second Quarter 2016 Financial Results and Provides Portfolio Update 30
May 03, 2016: Rigel Announces First Quarter 2016 Financial Results 33
Mar 08, 2016: Rigel Announces Fourth Quarter and Year End 2015 Financial Results 34
Corporate Communications 35
Mar 08, 2016: Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer 35
Product News 36
09/15/2016: Rigel Restructures to Focus on Fostamatinib Commercialization 36
04/12/2016: Rigel Announces Presentation on AMPK preclinical research project at Upcoming American Association of Cancer Research (AACR) Conference 37
04/12/2016: Rigel Announces Presentation on preclinical research project R191 at Upcoming American Association of Cancer Research (AACR) Conference 38
01/30/2017: Fostamatinib Study Results Continue to Trend Positive 39
01/07/2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco 40
Product Approvals 41
Apr 27, 2017: Rigel Announces Tavalisse as Proprietary Name for Fostamatinib in the United States 41
Apr 17, 2017: Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP 42
Clinical Trials 43
Oct 20, 2016: Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP 43
Aug 30, 2016: Rigel Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP 45
Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP 47
Feb 25, 2016: Rigel Initiates Phase II Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia 48
Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Rigel Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Rigel Enters into R&D Agreement with Bristol-Myers Squibb for TGF Beta Receptor Kinase Inhibitors 11
Proteros Biostructures Extends Collaboration With Rigel Pharma 11
Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 12
AstraZeneca Enters Into Licensing Agreement With Rigel Pharma For R256 13
Rigel Pharma Enters Into Licensing Agreement With BerGenBio For BGB324 14
Rigel Pharma Raises USD46 Million in Public Offering of Shares 15
Rigel Pharma to Raise up to USD30 Million in Private Placement of Shares 17
Rigel Pharma Completes Public Offering Of Shares For US$145 Million 18
Rigel Pharma Completes An Underwritten Public Offering Of US$130.4 Million 19
Rigel Pharmaceuticals Inc, Key Competitors 21
Rigel Pharmaceuticals Inc, Key Employees 22

List of Figures
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

News

  • Understanding the Need For Travel Vaccination
  • If you are getting ready for a particular trip that can see you away from your house for about a month or so, then it is necessary for you to take the help of travel vaccinations. Not ...
  • The Work Of The Ophthalmology Specialist
  • When we consider ophthalmology as a branch of science, it is actually about the treatment as well as getting to diagnose the different kinds of diseases and the disorder that is to ...
  • The Process Of Dental Implants And The Subsequent Recovery
  • In the United States of America, the fear of going to a dentist happens to rank number one on the list of children as well as adults. Most of the people are actually concerned when ...
  • The medication that can help the rural population
  • It is not always that you get to see world class hospitals in the rural areas, be it America or any other country. Hence, it is important that people actually take the help of tele-medication, ...
  • The Future of Telemedicine & Its Use
  • When talking about telemedicine, you do get to realize that it is the healthcare of the future. Most of the people do not realize the implications, and for more so the time, telemedicine ...

Get Updates

Share This Post

Recent Posts

© 2020 RnR Company Profiles. All rights reserved.